Cue Biopharma (CUE) vs Eledon Pharmaceuticals (ELDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Cue Biopharma (CUE) has outperformed Eledon Pharmaceuticals (ELDN) over the past year, losing 0.4% versus a loss of 16.8%. Over five years, ELDN leads with a -56.0% price change compared with -92.7% for CUE. Eledon Pharmaceuticals is the larger company by market cap ($201.5 million vs $200.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | ELDN |
|---|---|---|
| Share price | $27.66 | $2.48 |
| Market cap | $200.93M | $201.53M |
| 1-day change | +23.87% | +2.48% |
| YTD return | +202.30% | +64.24% |
| 1-year return | -0.43% | -16.78% |
| 5-year return | -92.68% | -55.95% |
| EPS (TTM) | $-29.59 | $-0.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $45.50 | $4.60 |
| 52-week low | $4.98 | $1.35 |
| Distance from 52-week high | -39.21% | -46.09% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +218.15% | +262.90% |
| Average volume | 266.83K | 935.08K |
| Shares outstanding | 7.26M | 81.26M |
| Employees | 29 | 33 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CUE has outperformed ELDN by 16.3 percentage points over the past year.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Eledon Pharmaceuticals
ELDN stock →Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
CUE vs ELDN FAQ
Which is bigger, Cue Biopharma or Eledon Pharmaceuticals?
Eledon Pharmaceuticals (ELDN) is larger, with a market capitalization of $201.53M compared with $200.93M for Cue Biopharma (CUE).
Which stock has performed better over the past year, CUE or ELDN?
CUE returned -0.43% over the past 12 months, compared with -16.78% for ELDN (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and Eledon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.